

ABL and Xi'an Tianlong Science and Technology Co., Ltd announce a distribution agreement conferring to ABL the ability to commercialize innovative real-time amplification (qPCR) instruments and reagents as well as RNA/DNA automated extraction solutions

ABL to launch its Life Science division and start the distribution of disruptive molecular biology instruments to be used for research purposes.

LUXEMBOURG VILLE, Luxembourg, December 27th, 2018 -- Advanced Biological Laboratories (ABL) S.A. today announced the official launch of its Life Science division to provide on a worldwide basis, innovative solutions around molecular biology. It is also proud to announce the execution of a distribution agreement with Xi'an Tianlong Science and Technology Co., Ltd to offer real-time amplification (qPCR) instruments and reagents as well as RNA/DNA extraction solutions in Europe, MEA, LATAM and USA including but not limited to the Gentier qPCR machines and Libex extractors.

"We are glad to expand our activities towards life science and build the capacity within the ABL Group to offer innovative products for molecular biology to our network of partners. We're also proud to bring new competencies on-board and establish sustainable partnerships with key companies like Xi'an Tianlong Science and Technology Co.,Ltd. to complete the portfolio of application currently covered by our Diagnostics, Clinical and Nadis divisions", said Dr. Chalom Sayada, CEO of ABL.

"We are excited to partner with ABL and help them providing breakthrough technology to molecular biology labs" said Mr.LiMing, general manager of Tianlong.

About ABL

Advanced Biological Laboratories (ABL), S.A., is a Diagnostic and Medical Software company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL's products offer to infectious disease clinicians, virology and microbiology laboratories optimal and efficient solutions (assays and software systems related to HIV, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu...) for sequencing (DeepChek®) clinical genotyping, viral load (UltraGene™) and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CROrelated services and assays manufacturing capacity. ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC® and the DPM used for data and patient management, monitoring and personalized

ADVANCED BIOLOGICAL LABORATORIES S.A.

17, rue des jardiniers L-1835 Luxembourg Tel: +352 26 38 96 76 Fax: + 352 26 38 96 76 31



reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products like ViroScore® Suite and DeepChek® are for research use only in the United States, and the data processing module is an FDA registered class I medical device. These are currently available for Research Use Only.

About Xi'an Tianlong Science and Technology Co.,Ltd.

Tianlong, an innovative high-technology company oriented in molecular diagnostic techniques from China. Since its foundation in 1997, TianLong keeps devoting itself to provide professional PCR detection devices, auxiliary reagents and high quality solution services for molecular diagnosis market. In 2012 Tianlong got investment from a multinational enterprise, SK which is ranked 57th of Global 500 enterprises.

Tianlong is a national high-tech enterprise, Tianlong obtained the medical devices and reagents production and operation licenses from SFDA, and also certified to ISO 13485 and ISO 9001 standards. The products of Tianlong include Nucleic Acid Extraction System, Real-time Quantitative PCR detection System, PCR Thermal Cycler, and all the related reagents including nucleic acid extraction kits, real-time PCR kits etc.

With the development of our market and the enrichment of our products, Tianlong has set up a distribution network covering all of mainland China. Meanwhile, Tianlong attends AACC in America, MEDICA in German, exhibitions in Brazil, Dubai and other important medical exhibitions to expand international market every year.

As one of the leading molecular diagnostic instruments company in China, Tianlong not only has the advantages in instrument field, but also fully enters the business in reagent field. A 1000 m2 GMP standard reagent manufacturing center was established in Suzhou Tianlong.

Today, Tianlong's products and services can be found all over the country. Inspired by the needs of our customers, we adopt advanced technologies and transform them into accessible innovation, bring technology to life.

Media Contact:

Dr Chalom Sayada, Advanced Biological Laboratories, +35226389676, contact@ablsa.com